Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | PHGDH | O43175 | 13/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20646750 | 0.88 | RXFP1 (0.46) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL43328 | 0.82 | KDM4E (0.66) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL17324809 | 0.82 | RXFP1 (0.64) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL13415456 | 0.81 | RXFP1 (0.62) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL11965202 | 0.79 | MCL1 (0.67) | PHGDHMEN1KMT2AMCL1 | |
| SCHEMBL24198804 | 0.78 | RXFP1 (0.59) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL1253301 | 0.78 | RXFP1 (0.72) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL22022199 | 0.78 | RXFP1 (0.59) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL4919697 | 0.78 | L3MBTL1 (0.70) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL19997267 | 0.78 | RXFP1 (0.59) | RXFP1PHGDHMEN1KMT2AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-14 | — | — | US | disclosed |
| US-9926282-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3252049-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | RXFP1 1737/4885PHGDH 2233/4885MEN1 576/4885 |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | RXFP1 1789/4885PHGDH 2215/4885MEN1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.